№ lp_1_2_43816
File format: docx
Character count: 27862
File size: 61 KB
The document outlines the principles and practices for maintaining data integrity in the pharmaceutical and biologics industries, offering a framework for companies to voluntarily adopt a Code of Conduct ensuring the reliability of data throughout the product lifecycle.
Note:
Year
Theme:
Data Integrity, Pharmaceutical Industry, Biologics
Document type:
Code of Conduct
Organization / institution:
Parenteral Drug Association (PDA)
Author:
Parenteral Drug Association (PDA)
Target audience:
Pharmaceutical and Biologics Industry Professionals
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Note:
Year
Subject:
Pharmaceutical Quality Information Summary
Document Type:
Template
Agency / Institution:
SAHPRA
Year:
2018
Region / City:
Fredericksburg, VA
Topic:
Biologics, Contracting, Medical Supplies
Document Type:
Contract Award Notice
Agency:
U.S. Department of Veterans Affairs
Author:
Not specified
Target Audience:
Contractors, Veterans Affairs
Period of Action:
From September 27, 2018
Approval Date:
September 27, 2018
Date of Changes:
Not specified
Year:
2023
Region / City:
Oxon Hill, Maryland
Topic:
Biologics, Biotechnology, Veterinary Health
Document Type:
Meeting Minutes
Organization:
USAHA Committee on Biologics and Biotechnology
Author:
Committee members and speakers
Target Audience:
Veterinary professionals, industry representatives, regulatory bodies
Period of Activity:
October 17, 2023
Approval Date:
October 17, 2023
Date of Changes:
Not indicated
Year:
Not specified
Region / City:
Not specified
Topic:
Pharmaceutical products, Drug validation
Document type:
Checklist
Organization / Institution:
MDA (Malaysian Drug Authority)
Author:
Not specified
Target audience:
Pharmaceutical companies, regulatory authorities
Validity period:
Not specified
Approval date:
Not specified
Amendment date:
Not specified
Language:
English
Keywords:
Drug product, Biologics, Validation, Pharmaceutical, Medical device
Year:
2013
Region / City:
EU
Subject:
Biologics, Biotechnology, Clinical Trials, Market Authorization
Document Type:
Clinical Trial and Market Authorization Process Overview
Organization:
NCL Innovations
Author:
NCL Innovations
Target Audience:
Healthcare professionals, regulatory bodies, pharmaceutical companies
Period of Validity:
Not specified
Approval Date:
Not specified
Amendment Date:
Not specified
Year:
2026
Region / City:
Not specified
Document Type:
Patient Directive / Legal Statement
Institution:
Hospital or affiliated medical facility
Author:
Patient (name not specified)
Target Audience:
Medical staff, legal representatives
Date of Document:
2026-03-06
Purpose:
To formally refuse vaccines, biologics, and biogenics during hospitalization
Method of Consent:
Signed by patient in presence of witnesses
Notarization:
Optional, recommended for legal validation
Year:
2025
Document Type:
Worksheet
Purpose:
Emergency use of unapproved drugs, biologics, or devices
Audience:
Investigators and Designated Reviewers
Regulatory Reference:
FDA IND, 21 CFR §50
Scope:
Life-threatening or severely debilitating conditions
Approval Requirement:
IRB reporting within 5 working days
Consent Requirement:
Informed consent from patient or legally authorized representative, exceptions documented
Certification:
Physician uninvolved in investigation must certify when consent cannot be obtained
Document ID:
HRP-322
Related Documents:
HRP-310, HRP-314, HRP-506
Year:
2025
Region / City:
Dorset, BCP Council
Theme:
Pharmaceutical Services, Health Needs Assessment
Document Type:
Draft Report
Organization:
Public Health Dorset
Author:
Jane Horne, Lee Robertson, Wilson Otitonaiye, Rohan Mongru, Fiona Arnold, Louise Bate
Target Audience:
Health professionals, policymakers, local authorities
Period of Validity:
2025-2028
Approval Date:
Draft version, ongoing review
Date of Last Update:
04/06/2025
Context:
This document provides a comprehensive pharmaceutical needs assessment for the Dorset area, focusing on the supply, demand, and gaps in pharmaceutical services over the period 2025-2028.
Year:
2014
Region / City:
Global
Topic:
Pharmaceutical Product Prequalification
Document Type:
Guideline
Organization / Institution:
World Health Organization (WHO)
Author:
World Health Organization
Target Audience:
Pharmaceutical manufacturers, regulatory bodies
Effective Period:
Not specified
Approval Date:
2014
Modification Date:
Not specified
Note:
Year
Topic:
Pharmaceutical product, regulatory approval, prequalification
Document type:
Template
Organization / institution:
WHO
Target audience:
Regulatory authorities, pharmaceutical manufacturers
Year:
2023
Region / City:
United Kingdom
Topic:
Pharmaceutical guidance
Document type:
Consultation response
Organization:
Royal Pharmaceutical Society
Author:
Royal Pharmaceutical Society
Target audience:
Pharmacy professionals, regulatory bodies, pharmacy service owners
Action period:
Not specified
Approval date:
Not specified
Date of changes:
Not specified
HDA Standard Pharmaceutical (Rx-only) Product and Medical Device Information Short Form Instructions
Note:
Year
Theme:
Pharmaceutical products, Medical devices
Document type:
Instructions, Form
Organization / Institution:
HDA
Target audience:
Distributors, Manufacturers, Supply chain professionals
Document type:
Regulatory template appendix
Subject:
Quality information summary for finished pharmaceutical products and vaccines
Procedure:
Reference SRA collaborative procedure
Regulatory framework:
WHO Guidelines on submission of documentation for prequalification
Issuing organization:
World Health Organization
Series:
WHO Technical Report Series
Series number:
No. 1010
Year:
2018
Scope:
Pharmaceutical products and vaccines approved by stringent regulatory authorities
Intended use:
National registration under the SRA collaborative procedure
Confidentiality status:
Includes confidential quality information
Approval basis:
Information as approved by the reference SRA
Change management:
Revision required upon approved variations affecting QIS-SRA (crp)
Organization:
World Health Organization; South African Health Products Regulatory Authority
Document type:
Regulatory guideline
Subject area:
Pharmaceutical quality documentation
Scope:
Multisource (generic) finished pharmaceutical products and active pharmaceutical ingredients
Applicable products:
Human medicines; biologics; veterinary medicines
Regulatory references:
WHO TRS 970 Annex 6; VICH guidelines; European Pharmacopoeia; USP; BP
Geographical applicability:
International; South Africa
Related regulatory procedures:
API Prequalification; CEP; APIMF; product dossier submission
Content focus:
Quality data requirements; labelling and product information; drug substance characterization
Intended users:
Marketing authorization applicants; regulatory assessors
Year:
2021
Region / City:
United States
Topic:
Pharmaceutical and Medical Device Product Information
Document Type:
Instructional Form
Organization / Institution:
Health Distribution Alliance (HDA)
Author:
Health Distribution Alliance
Target Audience:
Pharmaceutical distributors, medical device manufacturers, suppliers
Effective Period:
Not specified
Approval Date:
Not specified
Amendment Date:
2021
Year:
2023
Region / City:
Falkirk
Theme:
Health & Social Care, Pharmacy, Medication Management
Document Type:
Policy
Organization:
Falkirk Health & Social Care Partnership
Author:
Not specified
Target Audience:
Community pharmacies, care at home providers, healthcare professionals
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2022
Region / city:
Great Britain
Topic:
Remote hearings, Pharmacy, Patient safety
Document type:
Response to consultation
Organization:
Royal Pharmaceutical Society
Author:
Jonathan Lloyd Jones
Target audience:
General Pharmaceutical Council, Pharmacy professionals, Stakeholders
Validity period:
N/A
Approval date:
February 7, 2022
Amendment date:
N/A
Year:
2025
Region / City:
Australia
Topic:
Pharmaceutical benefits, chemotherapy, PBS
Document Type:
FAQ
Organization:
Pharmaceutical Benefits Scheme
Author:
Pharmaceutical Benefits Advisory Committee (PBAC)
Target Audience:
Healthcare providers, prescribers, patients
Effective Period:
From December 1, 2024
Approval Date:
Not specified
Modification Date:
Not specified
Contextual Description:
FAQ document providing detailed information on the changes in PBS listing for Opdualag and Vyxeos under the EFC Program, including prescription and claiming details.
Year:
2023
Country:
United Kingdom
Organisation:
Royal Pharmaceutical Society
Document type:
Evidence submission
Topic:
Inclusion and diversity in pharmacy services
Population focus:
LGBTQ+ communities
Methodology:
Mixed-methods survey and literature review
Sample size:
620 survey respondents
Data sources:
RPS I&D Programme evaluation survey; published academic studies
Status:
Unpublished internal survey with referenced published research
Scope:
Community and pharmacy professional services
Context:
Evidence submission to an LGBT+ health review drawing on an internal inclusion and diversity survey and recent pharmacy-focused research to describe experiences, barriers, and attitudes related to LGBTQ+ access to pharmacy services in the UK.